In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
 Burkert Pieske
Speaker
Burkert Pieske
Burkert Pieske Burkert Pieske

Charite - Campus Virchow-Klinikum (CVK) and German Heart Center, Berlin (Germany)

Speciality : Acute Heart Failure

Trained as Cardiologist in Munich, Freiburg, and Göttingen, Germany. Training in Basic Research in Boston, Philadelphia and Chicago, US, and Tokio, Japan. Professor of Cardiology since 2004. 2007 to 2014 Professor or Cardiology and Director of the Department of Cardiology at Medical University Graz, Austria. Founding Director of the Ludwig-Boltzmann Institute for Heart Failure Research in Graz, Austria. President of the Austrian Cardiac Society 2010-2012. Since 2014, BIH Professor of Cardiology and Director of the Departments of Internal Medicine and Cardiology at Charité University Medicine, Campus Virchow, and the German Heart Center, Berlin Germany. Principal Investigator of the German Center for Cardiovascular Research and at the Berlin Institute of Health (BIH). Basic, translational, and clinical research interests in the fields of Heart Failure, Heart Failure related Arrhythmias, and Clinical Trials. Study Chair of several ongoing Phase 2 and Phase 3 clinical trials.

55 presentations from this speaker

Classification of heart failure by ejection fraction should be maintained - PRO.

Event : ESC Congress 2020

  • Session : Controversies in Heart Failure: Classification by Ejection Fraction Should Be Maintained
  • Speaker : B Pieske (Berlin,DE)

Diagnostic algorithms for HFpEF.

Event : ESC Congress 2020

  • Session : Expert Advice - How Well Do We Know HFpEF?
  • Speaker : B Pieske (Berlin,DE)

Effect of Vericiguat on Left Ventricular Function: The VICTORIA Echocardiographic Sub-Study.

Event : HFA Discoveries 2020

  • Session : Late-Breaking Science Session 1 – Clinical Trial Update
  • Speaker : B Pieske (Berlin,DE)

Hot Line PARALLAX.

Event : ESC Congress 2020

  • Session : Hot Line PARALLAX
  • Speaker : BJ Mulder (Amsterdam,NL), F Ruschitzka (Zurich,CH), B Pieske (Berlin,DE), R De Boer (Groningen,NL)

How to implement VICTORIA results into clinical practice?

Event : ESC Congress 2020

  • Session : How To Implement Heart Failure Clinical Trial Results into Practice?
  • Speaker : B Pieske (Berlin,DE)

Late-Breaking Science Session 1 – Clinical Trial Update.

Event : HFA Discoveries 2020

  • Session : Late-Breaking Science Session 1 – Clinical Trial Update
  • Speaker : B Pieske (Berlin,DE), AM Jackson (Glasgow,GB), T Damy (Creteil,FR)

Panel discussion and live Q&A.

Event : ESC Congress 2020

  • Session : Therapeutic advances in HFrEF patients who have had a previous worsening HF event
  • Speaker : CS Lam (Singapore,SG), B Pieske (Berlin,DE), J Ezekowitz (Edmonton,CA), J Butler (Atlanta,US)
  • Sponsored by Bayer AG

Stimulating sGC: VICTORIA trial reveals improved outcomes in patients with HFrEF.

Event : ESC Congress 2020

  • Session : Therapeutic advances in HFrEF patients who have had a previous worsening HF event
  • Speaker : B Pieske (Berlin,DE)
  • Sponsored by Bayer AG

ABCs of diagnosis of HFpEF – What’s new?

Event : Heart Failure 2019

  • Session : Meet the experts on getting to grips with HFpEF
  • Speaker : B Pieske (Berlin,DE)
  • Organised by Medscape Education, supported with an educational grant from Novartis

Definition and diagnosis.The new HFA algorithm.

Event : Heart Failure 2019

  • Session : HFpEF: current diagnosis and management
  • Speaker : B Pieske (Berlin,DE)

Experts debate - Challenges faced in diagnosing and managing HFpEF.

Event : Heart Failure 2019

  • Session : Challenges faced in diagnosing and managing HFpEF
  • Speaker : CS Lam (Singapore,SG), JJV McMurray (Glasgow,GB), B Pieske (Berlin,DE), L Lund (Stockholm,SE), A Voors (Groningen,NL)
  • Organised by Medscape Education, supported with an educational grant from Novartis

Furthering our understanding of HFpEF to identify novel therapeutic targets

Event : ESC Congress 2019

  • Session : Expert Advice - Focus on heart failure with preserved ejection fraction (HFpEF)
  • Speaker : B Pieske (Berlin,DE)

HFpEF from mechanisms to diagnosis.

Event : Webinar 2019

  • Session : HFA Webinars 2019
  • Speaker : A Coats (Warwickshire,GB), R De Boer (Groningen,NL), B Pieske (Berlin,DE)

sGC stimulators.

Event : Heart Failure 2019

  • Session : Emerging treatment options in HFpEF
  • Speaker : B Pieske (Berlin,DE)

State of the Art - Diagnosis of heart failure with preserved ejection fraction: What's new?

Event : ESC Congress 2019

  • Session : Heart failure with preserved ejection fraction
  • Speaker : B Pieske (Berlin,DE)

Vericiguat.

Event : Heart Failure 2019

  • Session : Emerging therapies in heart failure
  • Speaker : B Pieske (Berlin,DE)
  • Joint Session with the working group on pharmacotherapy of the ESC

CAD patients with concomitant Heart Failure (HF): are current treatments enough?

Event : Heart Failure 2018

  • Session : Expanding the evidence in heart failure patients
  • Speaker : B Pieske (Berlin,DE)
  • Sponsored by Bayer AG

Case 2 - I don't need to escalate therapy when my HFrEF patients are stable!

Event : ESC Congress 2018

  • Session : Therapeutic dilemmas in heart failure : debate of the experts
  • Speaker : F Ruschitzka (Zurich,CH), M Jessup (Hingham,US), B Pieske (Berlin,DE)
  • Organised by Medscape Education, supported with an educational grant from Novartis

Dilemmas in heart failure management: what do the experts say?

Event : ESC Congress 2018

  • Session : Dilemmas in heart failure management: what do the experts say?
  • Speaker : CS Lam (Singapore,SG), B Pieske (Berlin,DE), S Solomon (Boston,US), F Ruschitzka (Zurich,CH), M Jessup (Hingham,US)
  • Organised by Medscape Education, supported with an educational grant by Novartis

Drugs - From failure to success?

Event : Heart Failure 2018

  • Session : What do I need to know about HFpEF
  • Speaker : B Pieske (Berlin,DE)

Introduction - Managing hypertension with a heavy heart

Event : ESC Congress 2018

  • Session : Meet the Experts - Managing hypertension with a heavy heart
  • Speaker : B Pieske (Berlin,DE)

Introduction - Seize the moment to optimize treatment for each patient with heart failure: why, when, and how.

Event : ESC Congress 2018

  • Session : Seize the moment to optimize treatment for each patient with heart failure: why, when, and how
  • Speaker : B Pieske (Berlin,DE)
  • Sponsored by Novartis Pharma AG

Panel discussion and audience Q&A.

Event : ESC Congress 2018

  • Session : Seize the moment to optimize treatment for each patient with heart failure: why, when, and how
  • Speaker : B Pieske (Berlin,DE), JJV McMurray (Glasgow,GB), R Wachter (Leipzig,DE), S Solomon (Boston,US)
  • Sponsored by Novartis Pharma AG

The new data in context: future perspectives for patients with heart failure.

Event : ESC Congress 2018

  • Session : New directions in the management of thrombotic risks in patients with heart failure
  • Speaker : B Pieske (Berlin,DE)
  • Sponsored by Bayer AG

The new HFA definition of HFpEF

Event : Heart Failure 2018

  • Session : HFpEF - The new HFA consensus
  • Speaker : B Pieske (Berlin,DE)

CRT in diastolic dysfunction: never? sometimes?

Event : EHRA 2017

  • Session : CRT: widening of the QRS or widening of the indications?
  • Speaker : B Pieske (Berlin,DE)
  • Joint Session with the Heart Failure Association of the ESC (HFA)

Symptomatic hypertensive heart disease: pathophysiology, consequences and treatment options

Event : ESC Congress 2017

  • Session : The hypertensive heart
  • Speaker : B Pieske (Berlin,DE)

Vericiquat.

Event : Heart Failure 2017

  • Session : Novel drugs in acute heart failure: hurdles, hype and hope
  • Speaker : B Pieske (Berlin,DE)

What do the Guidelines say?

Event : Heart Failure 2017

  • Session : Guidelines in Daily Practice III: pharmacological management based on LVEF
  • Speaker : B Pieske (Berlin,DE)

Ask the experts: your questions on optimizing heart failure management and the future of new treatments answered.

Event : Heart Failure 2016

  • Session : Ask the experts: your questions on optimizing heart failure management and the future of new treatments answered
  • Speaker : JJV McMurray (Glasgow,GB), B Pieske (Berlin,DE), F Ruschitzka (Zurich,CH), M Senni (Bergamo,IT)
  • Sponsored by Novartis Pharma AG

Benefits of a multidisciplinary approach when optimizing current and integrating new heart failure treatments for improved outcomes: panel discussion.

Event : Heart Failure 2016

  • Session : Optimizing current and integrating new treatments to improve outcomes in heart failure: practical insights
  • Speaker : F Ruschitzka (Zurich,CH), R Hobbs (Oxford,GB), T Jaarsma (Norrkoping,SE), J Riley (London,GB), B Pieske (Berlin,DE), M Senni (Bergamo,IT)
  • Sponsored by Novartis Pharma AG

cGMP activators

Event : ESC Congress 2016

  • Session : New hope for chronic heart failure therapy
  • Speaker : B Pieske (Berlin,DE)

Chronic heart failure (HFpEF and HFrEF).

Event : Heart Failure 2016

  • Session : Heart Failure 2016 Highlights
  • Speaker : B Pieske (Berlin,DE)

Diagnostic criteria.

Event : Heart Failure 2016

  • Session : What a clinician should know about heart failure with preserved ejection fraction
  • Speaker : B Pieske (Berlin,DE)

Discussion: acting at the core of cardiovascular disease: new perspectives.

Event : ESC Congress 2016

  • Session : Acting at the core of cardiovascular disease: new perspectives
  • Speaker : B Pieske (Berlin,DE)
  • Organised by Universitätsklinikum Des Saarlandes / Course Director: Prof Michael Böhm / Supported by an unrestricted educational grant from SERVIER

Heart failure with preserved ejection fraction: how to optimise management.

Event : Heart Failure 2016

  • Session : The new ESC Guidelines: Focus on chronic heart failure
  • Speaker : B Pieske (Berlin,DE)

HFpEF genes- Are there any?

Event : ESC Congress 2016

  • Session : Taking heart failure genetics to the clinic
  • Speaker : B Pieske (Berlin,DE)

HFpEF in NYHA III with LVEF 48% increased heart rate, increased NT-BNP, and T2DM - What to do? What do the Guidelines say?

Event : ESC Congress 2016

  • Session : Common difficult decisions in heart failure
  • Speaker : B Pieske (Berlin,DE)

Optimising current and integrating new treatments: experience from clinical practice (part A).

Event : Heart Failure 2016

  • Session : Optimizing current and integrating new treatments to improve outcomes in heart failure: practical insights
  • Speaker : B Pieske (Berlin,DE)
  • Sponsored by Novartis Pharma AG

Optimizing treatment for heart failure with reduced ejection fraction patients following stabilization after an acute decompensation of heart failure episode.

Event : ESC Congress 2016

  • Session : Optimizing outcomes in patients with heart failure with reduced ejection fraction: evidence and clinical experience sharing
  • Speaker : B Pieske (Berlin,DE)
  • Sponsored by Novartis Pharma AG

Patient management after Transcatheter Mitral Valve Repair.

Event : ESC Congress 2016

  • Session : Living vs Surviving: treating mitral regurgitation with Transcatheter Mitral Valve Repair in 2016
  • Speaker : AP Kappetein (Rotterdam,NL), B Pieske (Berlin,DE), A Vahanian (Vincennes,FR), F Maisano (Zurich,CH), MJ Swaans (Hedel,NL)
  • Sponsored by Abbott Vascular

Rationalizing targets in cardiovascular disease.

Event : ESC Congress 2016

  • Session : Acting at the core of cardiovascular disease: new perspectives
  • Speaker : B Pieske (Berlin,DE)
  • Organised by Universitätsklinikum Des Saarlandes / Course Director: Prof Michael Böhm / Supported by an unrestricted educational grant from SERVIER

The interplay between mitral regurgitation and heart failure worsening.

Event : ESC Congress 2016

  • Session : Living vs Surviving: treating mitral regurgitation with Transcatheter Mitral Valve Repair in 2016
  • Speaker : B Pieske (Berlin,DE)
  • Sponsored by Abbott Vascular

Vericiguat.

Event : Heart Failure 2016

  • Session : Drugs in the pipeline for acute heart failure
  • Speaker : B Pieske (Berlin,DE)

Chronic heart failure (HFpEF and HFrEF).

Event : Heart Failure 2015

  • Session : Heart Failure 2015 Highlights
  • Speaker : B Pieske (Berlin,DE)

Comorbidities, differential diagnosis and phenotypic spectrum of heart failure with preserved ejection fraction.

Event : Heart Failure 2015

  • Session : What's hot in heart failure: defining unmet medical needs and innovative targets for therapy
  • Speaker : B Pieske (Berlin,DE)
  • Sponsored by Bayer Healthcare

Introduction.

Event : Heart Failure 2015

  • Session : What's hot in heart failure: defining unmet medical needs and innovative targets for therapy
  • Speaker : B Pieske (Berlin,DE)
  • Sponsored by Bayer Healthcare

The future

Event : ESC Congress 2015

  • Session : Heart failure with preserved ejection fraction - What we know, what we don't know, and where we are going
  • Speaker : B Pieske (Berlin,DE)

Treating comorbidities.

Event : Heart Failure 2015

  • Session : Heart failure with preserved ejection fraction: what we know and we don't know
  • Speaker : B Pieske (Berlin,DE)

Guanylate cyclase activators.

Event : ESC Congress 2014

  • Session : Emerging therapies in acute heart failure
  • Speaker : B Pieske (Berlin,DE)

An octagenarian with preserved ejection fraction.

Event : ESC Congress 2013

  • Session : Exercise and heart failure
  • Speaker : B Pieske (Berlin,DE)

Panel.

Event : ESC Congress 2013

  • Session : Exercise and heart failure
  • Speaker : S Adamopoulos (Athens,GR), U Corra (Veruno,IT), T Jaarsma (Norrkoping,SE), B Pieske (Berlin,DE), JP Schmid (Barmelweid,CH)

What could be new in the 2014 recommendations.

Event : ESC Congress 2013

  • Session : Challenges in heart failure with preserved ejection fraction
  • Speaker : B Pieske (Berlin,DE)

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are